BRIUMVI UBLITUXIMAB-XIIY 150 MG/6ML INJECTION FOR IV
Live / Registered — Registered (as of 24 Dec 2024)
What this means for you
Registered since 24 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97715586
- Registration number
- 7627246
- Mark type
- Design + words
- Filed
- 13 Dec 2022
- Published for opposition
- 11 Jul 2023
- Registered
- 24 Dec 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for human use, namely, pharmaceutical preparations for the prevention and treatment of central nervous system disorders, multiple sclerosis, autoimmune diseases and B-cell mediated non-oncological diseases, the foregoing featuring monoclonal antibodies
Owner
- TG THERAPEUTICS, INC., New York, NY, US
- TG THERAPEUTICS, INC., New York, NY, US
- TG THERAPEUTICS, INC., New York, NY, US
Prosecution history
- 24 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 03 Dec 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 03 Dec 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 05 Nov 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 04 Sept 2024 — USE AMENDMENT FILED
- 05 Nov 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 04 Sept 2024 — TEAS STATEMENT OF USE RECEIVED
- 05 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Mar 2024 — SOU EXTENSION 1 GRANTED
- 04 Mar 2024 — SOU EXTENSION 1 FILED
- 04 Mar 2024 — SOU TEAS EXTENSION RECEIVED
- 05 Sept 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Jul 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Jul 2023 — PUBLISHED FOR OPPOSITION